Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 51

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 51
---
 % | ​                                                                       | ​ |
| Lauren Riker             | ​ | ​ | ​                  | ​ |  75 | % | ​ | ​ | ​ | ​                     | ​ | 25 | % | ​                                                                       | ​ |
| Charles A. Reinhart, III | ​ | ​ | ​                  | ​ |  75 | % | ​ | ​ | ​ | ​                     | ​ | 25 | % | ​                                                                       | ​ |
| Kristen Williams         | ​ | ​ | ​                  | ​ |  75 | % | ​ | ​ | ​ | ​                     | ​ | 25 | % | ​                                                                       | ​ |
| Daryl Gaugler            | ​ | ​ | ​                  | ​ |  75 | % | ​ | ​ | ​ | ​                     | ​ | 25 | % | ​                                                                       | ​ |
| Jonathan Slonin          | ​ | ​ | ​                  | ​ |  75 | % | ​ | ​ | ​ | ​                     | ​ | 25 | % | ​                                                                       | ​ |

(1) Messrs. Lee and Stack do not have an individual performance rating as Chief Executive Officer. Their annual incentive bonuses are entirely tied to company performance. Our People & Compensation Committee assesses the achievement of corporate and individual goals and performance at the end of each fiscal year to determine the appropriate bonus for each named executive officer. In addition to financial goals, other factors considered in determining performance include corporate goals related to manufacturing, clinical, regulatory, marketing, and business development, among others. The 2024 annual incentive bonus was paid at a corporate factor 90% of target, which reflects the Company’s 2024 operational and financial performance. The People & Compensation Committee approved the Company’s annual incentive bonuses at a corporate factor of 90% of target for all named executive officers, reflecting the fact that we: • achieved our revenue targets while implementing significant organization changes required to lay the foundation for future growth; • received FDA approval of our sNDA for an enhanced, large-scale manufacturing suite for EXPAREL at our Science Center Campus in San Diego, California;

64 | investor.pacira.com

TABLE OF CONTENTS Executive Compensation • were granted RMAT designation for PCRX-201 (enekinragene inzadenovec), our novel, intra-articular HCAd gene therapy product candidate. RMAT designation is a dedicated program designed to expedite the development and review processes for promising therapies—including genetic therapies—that are